

CV Sciences Certificate of Analysis



This document is to certify that units of the lot number below were tested and found to comply with CV Sciences finished product specifications.

SAMPLE ID:**PRODUCT NAME:**

Strength:

Lot Number:

Expiration Date:

CANNABINOIDS***MG/UNIT****METHOD**

CBD

CBDA

d9-THC

THCA-A

d8-THC

THCV

CBDV

CBDVA

CBGA

CBG

CBN

CBC

CBL

Total Cannabinoids

Sample Size

THC by Mass

HEAVY METALS***STATUS (PASS/FAIL)****METHOD**

Arsenic

Cadmium

Mercury

Lead

CV Sciences Certificate of Analysis



MICROBIOLOGY*	STATUS (PASS/FAIL)	METHOD
Mold/Mildew/Yeast		
Aerobic Bacteria		
Coliforms		
E. Coli		
Salmonella		
Pseudomonas		

PESTICIDES**	STATUS (PASS/FAIL)	METHOD
Total Pesticides		
Mycotoxins	Pass	

RESIDUAL SOLVENTS**	STATUS (PASS/FAIL)	METHOD
Total Residual Solvents		

1. The hemp extract is the product of a batch tested by the independent testing laboratory;
2. The batch contained a total delta-9-tetrahydrocannabinol concentration that did not exceed 0.3 percent pursuant to the testing of random sample of the batch; and
3. The batch does not contain contaminants unsafe for human consumption.[†]

[†]Tested analytes and limits were set by CV Sciences, Inc.

DB Labs Sample ID #:

*Actual analytical results obtained by DB Labs (Las Vegas, NV), CV Sciences' third-party testing laboratory.

Anresco Laboratories Sample ID #:

**Actual analytical results obtained by Anresco Laboratories (San Francisco, CA), CV Sciences' third-party testing laboratory.

QUALITY APPROVAL

Prepared By / Date	Approved By / Date	Status
Vandana Kothari	<div><div><div>Signed by Vandana Kothari</div></div><div><div>I approve this document</div><div>11-Apr-2025 09:41 PDT</div></div></div> <div>87A410FFF032487389008EED0868E359</div>	



April 08, 2025

CV SCIENCES, INC.
 9530 Padgett Street, Suite 107
 San Diego, CA 92126

 Order No. 569897
 Sample No. 1294607
SAMPLE INFORMATION

Description FP-25-0027 PlusCBD Extra strength Softgels 15mg 90ct SKU 389 exp 02/27
Lot Number 52638
Category (Type) Non-Inhalable Edible (Capsule)
Received April 04, 2025

ANALYTICAL RESULTS

Analysis Cannabinoid Profile (Non-Plant) ✔ Pass
Instrument Liquid Chromatography Diode Array Detector (LC-DAD)
Method MF-CHEM-15
Analysis Date April 04, 2025 to April 08, 2025

Cannabinoid	mg/g	%	mg/serving	mg/package	Labeled mg/serving	% Difference	Status
Δ8-THC	ND	ND	ND	ND	-	-	-
Δ9-THC	<LOQ	<LOQ	<LOQ	<LOQ	-	-	Pass
Δ9-THCA	ND	ND	ND	ND	-	-	-
THCV	ND	ND	ND	ND	-	-	-
THCVA	ND	ND	ND	ND	-	-	-
CBD	39.32	3.932	16.32	1468.95	15	8.81	-
CBDA	ND	ND	ND	ND	-	-	-
CBC	ND	ND	ND	ND	-	-	-
CBCA	ND	ND	ND	ND	-	-	-
CBDV	<LOQ	<LOQ	<LOQ	<LOQ	-	-	-
CBG	<LOQ	<LOQ	<LOQ	<LOQ	-	-	-
CBGA	ND	ND	ND	ND	-	-	-
CBN	ND	ND	ND	ND	-	-	-
Total THC	<LOQ	<LOQ	<LOQ	<LOQ	-	-	-
Total CBD	39.32	3.932	16.32	1468.95	-	-	-
Total Cannabinoids	39.32	3.932	16.32	1468.95	-	-	-
Sum of Cannabinoids	39.32	3.932	16.32	1468.95	-	-	-
Serving Weight (g)	0.4151						
Package Weight (g)	37.36						

Comments

The reported result for delta-9 THC represents the quantitation of a peak that elutes in the retention time window of the delta-9 THC certified reference standard. However, it is inconclusive due to the interference of an unknown compound. LC-MS/MS analysis is recommended for a more conclusive identification and quantitation.

 Reported by
Anresco, Inc.

NT = Not Tested
 ND = None Detected
 LOD = Limit of Detection (0.1333 mg/g)
 LOQ = Limit of Quantitation (0.4000 mg/g)
 Total THC = Δ8-THC + Δ9-THC + (0.877 * THCA)
 Total CBD = CBD + (0.877 * CBDA)
 Total Cannabinoids = Σ (neutral cannabinoids) + [0.877 * Σ (acidic cannabinoids)]

 Donald Lao
 Analyst II


April 08, 2025

 If there are any questions with this report, please contact "compliance@anresco.com".

April 08, 2025

CV SCIENCES, INC.

9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 569897

Sample No. 1294607

SAMPLE INFORMATION

Description FP-25-0027 PlusCBD Extra strength Softgels 15mg 90ct SKU 389 exp 02/27
Lot Number 52638
Category (Type) Non-Inhalable Edible (Capsule)
Received April 04, 2025

ANALYTICAL RESULTS

Analysis Pesticide Screen ✔ Pass
Instrument Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method MF-CHEM-13
Analysis Date April 04, 2025 to April 08, 2025

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Abamectin	0.04/0.10	ND	0.3	Pass
Acephate	0.02/0.06	ND	5.0	Pass
Acequinocyl	0.04/0.10	ND	4.0	Pass
Acetamiprid	0.017/0.05	ND	5.0	Pass
Aldicarb	0.02/0.06	ND	0.02	Pass
Azoxystrobin	0.02/0.06	ND	40.0	Pass
Bifenazate	0.02/0.06	ND	5.0	Pass
Bifenthrin	0.04/0.10	ND	0.5	Pass
Boscalid	0.02/0.06	ND	10.0	Pass
Captan	0.2/0.6	ND	5.0	Pass
Carbaryl	0.02/0.06	ND	0.5	Pass
Carbofuran	0.017/0.05	ND	0.017	Pass
Chlorantraniliprole	0.02/0.06	ND	40.0	Pass
Chlordane	0.02/0.06	ND	0.02	Pass
Chlorfenapyr	0.02/0.06	ND	0.02	Pass
Chlorpyrifos	0.02/0.06	ND	0.02	Pass
Clofentezine	0.02/0.06	ND	0.5	Pass
Coumaphos	0.02/0.06	ND	0.02	Pass
Cyfluthrin	0.10/0.30	ND	1.0	Pass
Cypermethrin	0.10/0.30	ND	1.0	Pass
Daminozide	0.017/0.05	ND	0.017	Pass
DDVP (Dichlorvos)	0.013/0.04	ND	0.013	Pass
Diazinon	0.017/0.05	ND	0.2	Pass
Dimethoate	0.017/0.05	ND	0.017	Pass
Dimethomorph	0.017/0.05	ND	20.0	Pass
Ethoprop(hos)	0.02/0.06	ND	0.02	Pass
Etofenprox	0.02/0.06	ND	0.02	Pass
Etoxazole	0.02/0.06	ND	1.5	Pass
Fenhexamid	0.017/0.05	ND	10.0	Pass
Fenoxycarb	0.02/0.06	ND	0.02	Pass
Fenpyroximate	0.02/0.06	ND	2.0	Pass

If there are any questions with this report, please contact "compliance@anresco.com".

Certificate of Analysis

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Fipronil	0.02/0.06	ND	0.02	Pass
Flonicamid	0.02/0.06	ND	2.0	Pass
Fludioxonil	0.02/0.06	ND	30.0	Pass
Hexythiazox	0.02/0.06	ND	2.0	Pass
Imazalil	0.02/0.06	ND	0.02	Pass
Imidacloprid	0.02/0.06	ND	3.0	Pass
Kresoxim Methyl	0.02/0.06	ND	1.0	Pass
Malathion	0.017/0.05	ND	5.0	Pass
Metalaxyl	0.017/0.05	ND	15.0	Pass
Methiocarb	0.02/0.06	ND	0.02	Pass
Methomyl	0.013/0.04	ND	0.1	Pass
Methyl parathion	0.02/0.06	ND	0.02	Pass
Mevinphos	0.02/0.06	ND	0.02	Pass
Myclobutanil	0.02/0.06	ND	9.0	Pass
Naled	0.017/0.05	ND	0.5	Pass
Oxamyl	0.013/0.04	ND	0.2	Pass
Paclobutrazol	0.02/0.06	ND	0.02	Pass
Pentachloronitrobenzene	0.017/0.05	ND	0.2	Pass
Permethrins	0.10/0.30	ND	20.0	Pass
Phosmet	0.02/0.06	ND	0.2	Pass
Piperonyl Butoxide	0.017/0.05	ND	8.0	Pass
Prallethrin	0.04/0.10	ND	0.4	Pass
Propiconazole	0.02/0.06	ND	20.0	Pass
Propoxur	0.013/0.04	ND	0.013	Pass
Pyrethrins	0.15/0.50	ND	1.0	Pass
Pyridaben	0.017/0.05	ND	3.0	Pass
Spinetoram	0.02/0.06	ND	3.0	Pass
Spinosad	0.02/0.06	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.02/0.06	ND	13.0	Pass
Spiroxamine	0.017/0.05	ND	0.017	Pass
Tebuconazole	0.02/0.06	<LOQ (0.051)	2.0	Pass
Thiacloprid	0.013/0.04	ND	0.013	Pass
Thiamethoxam	0.02/0.06	ND	4.5	Pass
Trifloxystrobin	0.02/0.06	ND	30.0	Pass

Reported by
Anresco, Inc.

NT = Not Tested
 ND = None Detected
 LOD = Limit of Detection
 LOQ = Limit of Quantitation

Seonmin Lee
 Analyst II



April 08, 2025

If there are any questions with this report, please contact "compliance@anresco.com".

April 08, 2025

CV SCIENCES, INC.9530 Padgett Street, Suite 107
San Diego, CA 92126Order No. 569897
Sample No. 1294607

SAMPLE INFORMATION

Description FP-25-0027 PlusCBD Extra strength Softgels 15mg 90ct SKU 389 exp 02/27
Lot Number 52638
Category (Type) Non-Inhalable Edible (Capsule)
Received April 04, 2025

ANALYTICAL RESULTS

Analysis Residual Solvent Screen ✔ Pass
Instrument Gas Chromatography Mass Spectrometry (GC/MS)
Method MF-CHEM-32
Analysis Date April 04, 2025 to April 08, 2025

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
1,2-Dichloroethane	0.5/0.5	ND	1	Pass
Acetone	57/200	ND	5000	Pass
Acetonitrile	56/200	ND	410	Pass
Benzene	0.5/0.5	ND	1	Pass
n-Butane	45/200	ND	5000	Pass
Chloroform	0.5/0.5	ND	1	Pass
Ethanol	37/200	ND	5000	Pass
Ethyl acetate	38/200	ND	5000	Pass
Ethyl ether	37/200	ND	5000	Pass
Ethylene oxide	0.1/0.5	ND	1	Pass
n-Heptane	135/200	ND	5000	Pass
n-Hexane	49/200	ND	290	Pass
Isopropyl alcohol	57/200	ND	5000	Pass
Methanol	37/200	ND	3000	Pass
Methylene chloride	0.1/0.5	ND	1	Pass
n-Pentane	37/200	ND	5000	Pass
Propane	72/200	ND	5000	Pass
Toluene	49/200	ND	890	Pass
Total xylenes (ortho-, meta-, para-)	58/200	ND	2170	Pass
Trichloroethylene	0.5/0.5	ND	1	Pass

Reported by
Anresco, Inc.

NT = Not Tested
ND = None Detected
LOD = Limit of Detection
LOQ = Limit of Quantitation


Jordean Vargas
Analyst III

April 08, 2025

If there are any questions with this report, please contact "compliance@anresco.com".

April 08, 2025

CV SCIENCES, INC.

9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 569897

Sample No. 1294607

SAMPLE INFORMATION

Description FP-25-0027 PlusCBD Extra strength Softgels 15mg 90ct SKU 389 exp 02/27
Lot Number 52638
Category (Type) Non-Inhalable Edible (Capsule)
Received April 04, 2025

ANALYTICAL RESULTS

Analysis Mycotoxins Screen ✔ Pass
Instrument Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method MF-CHEM-13
Analysis Date April 04, 2025 to April 08, 2025

Analyte	LOD/LOQ (ppb)	Findings (ppb)	Limit (ppb)	Status
Aflatoxin B1	2/5	ND	-	-
Aflatoxin B2	2/5	ND	-	-
Aflatoxin G1	2/5	ND	-	-
Aflatoxin G2	2/5	ND	-	-
Total Aflatoxins	8/20	ND	20	Pass
Ochratoxin A	6/18	ND	20	Pass

Reported by
Anresco, Inc.

NT = Not Tested
ND = None Detected
LOD = Limit of Detection
LOQ = Limit of Quantitation

Seonmin Lee
Analyst II



April 08, 2025

If there are any questions with this report, please contact "compliance@anresco.com".

April 08, 2025

CV SCIENCES, INC.

9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 569897
Sample No. 1294607

SAMPLE INFORMATION

Description FP-25-0027 PlusCBD Extra strength Softgels 15mg 90ct SKU 389 exp 02/27
Lot Number 52638
Received April 04, 2025

ANALYTICAL RESULTS

Analysis Date April 04, 2025 to April 08, 2025

Findings	Analysis	Results	Method
	Standard Plate Count	<10 cfu/g	FDA BAM
	Yeast	<10 cfu/g	FDA BAM
	Mold	<10 cfu/g	FDA BAM
	Coliforms	<10 cfu/g	FDA BAM - ECC AGAR
	Escherichia coli	<10 cfu/g	FDA BAM - ECC AGAR
	Salmonella	Negative /10g	MF-MICRO-11 (AOAC 2016.01)

Reported by
Anresco, Inc.


Allen Zhu
Analyst

If there are any questions with this report, please contact "compliance@anresco.com".

page 1 of 1



Certificate of Analysis

April 08, 2025

CV SCIENCES, INC.
9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 569897
Sample No. 1294607

SAMPLE INFORMATION

Description FP-25-0027 PlusCBD Extra strength Softgels 15mg 90ct SKU 389 exp 02/27
Lot Number 52638
Category (Type) Non-Inhalable Edible (Capsule)
Received April 04, 2025

ANALYTICAL RESULTS

Analysis Heavy Metals ✔ Pass
Instrument Inductively Coupled Plasma Mass Spectrometry (ICP-MS)
Method MF-CHEM-16
Analysis Date April 04, 2025 to April 08, 2025

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Arsenic	0.003/0.05	<LOQ	1.5	Pass
Cadmium	0.008/0.05	ND	0.5	Pass
Mercury	0.002/0.05	ND	3	Pass
Lead	0.01/0.125	ND	0.5	Pass

Reported by
Anresco, Inc.

NT = Not Tested
ND = None Detected
LOD = Limit of Detection
LOQ = Limit of Quantitation



Eric Tam
Senior Chemist

April 08, 2025

If there are any questions with this report, please contact "compliance@anresco.com".

Certificate Of Completion

Envelope Id: FB695C4F-E1E2-4333-99D1-9FDEF0D80F12
 Subject: FP-25-0027 PlusCBD Extra strength Softgels 15mg 90ct.pdf
 Source Envelope:
 Document Pages: 9
 Certificate Pages: 1
 AutoNav: Enabled
 Envelopeld Stamping: Enabled
 Time Zone: (UTC-08:00) Pacific Time (US & Canada)

Status: Completed

 Envelope Originator:
 Vandana Kothari
 vandana.kothari@cvsciences.com
 IP Address: 64.207.219.8

Record Tracking

Status: Original
 4/11/2025 9:39:50 AM
 Holder: Vandana Kothari
 vandana.kothari@cvsciences.com
 Location: DocuSign

Signer Events

Vandana Kothari
 vandana.kothari@cvsciences.com
 DIRECTOR OF QUALITY
 CV Sciences - Part 11
 Security Level: Email, Account Authentication
 (Required)

Signature

Vandana Kothari

 Signature Adoption: Pre-selected Style
 Signature ID:
 87A410FF-F032-4873-8900-BEED0868E359
 Using IP Address: 75.85.176.253

 With Signing Authentication via Docusign password
 With Signing Reasons (on each tab):
 I approve this document

Timestamp

Sent: 4/11/2025 9:40:39 AM
 Viewed: 4/11/2025 9:41:28 AM
 Signed: 4/11/2025 9:41:58 AM

Electronic Record and Signature Disclosure:
 Not Offered via Docusign

In Person Signer Events

Signature

Timestamp

Editor Delivery Events

Status

Timestamp

Agent Delivery Events

Status

Timestamp

Intermediary Delivery Events

Status

Timestamp

Certified Delivery Events

Status

Timestamp

Carbon Copy Events

Status

Timestamp

Witness Events

Signature

Timestamp

Notary Events

Signature

Timestamp

Envelope Summary Events

Status

Timestamps

Envelope Sent	Hashed/Encrypted	4/11/2025 9:40:39 AM
Certified Delivered	Security Checked	4/11/2025 9:41:28 AM
Signing Complete	Security Checked	4/11/2025 9:41:58 AM
Completed	Security Checked	4/11/2025 9:41:58 AM

Payment Events

Status

Timestamps